Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners. Thanx for your patience as we catch-up.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on development of adaptable non-absorbed polymeric drugs to for congestive heart failure, chronic kidney disease, end stage renal disease and hypertension, closed a $36M Series B financing. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem. Thanx for your patience as [...]

SpineVision (France) a commercial-stage medical device company focused on spine deformities, lumbar degenerative disc diseases and cervical disorders, closed a $5M Series B financing. Participants include Partner Capital, Sofinnova Ventures, BroadPeak, HealthCap, Innoven and Edbi. Thanx for your patience as we catch-up.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on cardiovascular and renal disorders, closed a $36M Series B financing, bringing the total round to $53M. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.

NextWave Pharmaceuticals (Cupertino, CA) a clinical-stage specialty pharmaceutical focused on cardiovascular and CNS diseases, closed a $45M Series C financing. Participants include Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.

Omthera Pharmaceuticals (Bedminster, NJ) a clinical-stage specialty biopharma company focused on an Omega-3 fatty acid containing DHA and EPA as a therapy for dyslipidemia, closed a $33.9M Series B financing. Participants include New Enterprise Associates and Sofinnova Ventures.

Aerie Pharmaceuticals (Bridgewater, NJ) a clinical-stage biotechnology company focused on the treatment of glaucoma and other ophthalmic disease, closed a $41.3M Series B financing. Participants include Alta Partners and Sofinnova Ventures.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on end stage renal disease, congestive heart failure, chronic kidney disease, and hypertension, closed a $21M Series B financing. Participants include AgeChem, CMEA Capital, ARCH Venture Partners, Sofinnova Ventures and Dow Venture Capital.

Flexion Therapeutics (Woburn, MA) a clinical-stage biopharma focused on autoimmune disease, ulcerative colitis and tinnitus, closed a $9M Series A financing, bringing the total round to $42M. Participants include Pfizer Venture Investments, Versant Ventures, 5AM Ventures and Sofinnova Ventures.

Flexion Therapeutics (Woburn, MA) advances high value specialty drug candidates through clinically meaningful proof of concept and beyond, the company plans to announce deals with three major pharmas shortly, closed a $33M Series A financing. Participants include Versant Ventures, 5AM Ventures and Sofinnova Ventures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

  

to top of page...